Exon-skipping therapy for Duchenne muscular dystrophy

[1]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[2]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[3]  A. Nakamura,et al.  In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  A. Nakamura,et al.  Exon‐skipping therapy for Duchenne muscular dystrophy , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[5]  Akinori Nakamura,et al.  Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs , 2009, Annals of neurology.

[6]  P. Iversen,et al.  Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  A. Nakamura,et al.  Follow-up of three patients with a large in-frame deletion of exons 45–55 in the Duchenne muscular dystrophy (DMD) gene , 2008, Journal of Clinical Neuroscience.

[8]  I. Graham,et al.  Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.

[9]  K. Nagaraju,et al.  Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy , 2007, Expert opinion on biological therapy.

[10]  Christophe Béroud,et al.  Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.

[11]  S. Wilton,et al.  Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide , 2006, The journal of gene medicine.